Drugs / AMG 986
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03318809 | Dec 2017 → Mar 2018 | heart failure | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT03276728 | Aug 2016 → Apr 2019 | heart failure | Amgen | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 986 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03318809 ↗ |
| Action | Activate | “AMG 986 is a novel apelin receptor (APJ) agonist that improves cardiac contractility in animal models without adversely impacting hemodynamics.” PMID 35460392 ↗ Apr 2022 |
| Route | Intravenous | “by continuous IV infusion or by oral administration” NCT03276728 ↗ |
| Route | Oral | “by continuous IV infusion or by oral administration” NCT03276728 ↗ |